Search our Trials

Search Results

Trial Number
Mechanism of Action
Drug Classifications
Target Required
Conditions
Site
    20-08
    TAK-676 is a synthetic cyclic dinucleotide (CDN) exhibiting highly selective binding and activation of STING pathway. 
    Immunotherapy, targeted
    Not Required
    Colorectal Cancer, Head and Neck Cancer, Solid Tumor
    MCD
    20-13
    NT-I7 is a human IL-7 fusion protein that promotes T cell development which plays a central role in immune response.
    Cytokines, Immunotherapy
    Not Required
    Colorectal Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer, Solid Tumor, Triple Negative Breast Cancer
    MCD
    20-23
    THOR-707, the IL-2 variant moiety binds to dimers containing the IL-2 receptor beta and gamma chains (IL2Rbg; IL2Rbetagamma) on immune cells activating these cells and...
    recombinant human IL-2 variant
    Not Required
    Solid Tumor
    MCD
    20-26
    GDC-0077 – PI3K inhibitor Idasanutlin – MDM2 protein antagonist Alectinib – ALK kinase inhibitor Trastuzumab Emtansine – HER2 antibody-drug conjugate Ipatasertib – AKT inhibitor Atezolizumab...
    Antibody Drug Conjugate, Monoclonal Antibody, Small Molecule, Targeted Therapy
    [ROS1 fusion] tumors, [AKT1/2/3 mutant] tumors, [HER2 mutant] tumors, [MDM2-amplified, TP53 wild-type] tumors, [PIK3CA multiple mutant] tumors, [NTRK 1/2/3 fusion] tumors, [ALK fusion] tumors, TMB-high...
    Solid Tumor
    MCD
    21-04
    AdAPT-001 is an oncolytic adenovirus that expresses a TGF-β (beta) trap fusion protein
    Oncolytic virus
    Not Required
    Solid Tumor
    MCD
    21-12
    ON 123300 is a small molecule, dual inhibitor of CDK4/6 and ARK5, a key enzyme controlling cellular energy homeostasis. Inhibition of ARK5 by ON 123300...
    Small Molecule
    Not Required
    Solid Tumor
    MCD
    21-25
    BI 1810631 is an EGFR wild type sparing, selective HER2 inhibitor with potent inhibitory activity on all oncogenic HER2 mutations including the HER2 YVMA insertion...
    Targeted Therapy
    HER2
    Non-Small Cell Lung Cancer, Solid Tumor
    MCD
    21-41
    ASP1570 is a small molecule immuno-oncology agent that is expected to act through the activation of immune cells in the tumor microenvironment.
    Immunotherapy (Targeted), Small Molecule
    Not Required
    Melanoma, Non-Small Cell Lung Cancer, Solid Tumor
    MCD
    21-43
    S095029 (Sym025) is a monoclonal antibody candidate against NKG2A, a receptor for natural killer cells.
    human monoclonal IgG1 antibody that targets the human cell surface molecule NKG2A (CD159a) and blocks interaction with its ligand HLA-E.
    Not Required
    Solid Tumor
    MCD
    22-02
    IMP9064 is designed to inhibit the function of ATR, a component of the DNA damage repair system in all cells. Inhibition of DNA damage repair...
    ATR inhibitor
    PARP& ATR
    Solid Tumor
    MCD
    22-04
    BAL0891 is a small-molecule inhibitor of TTK and PLK1 . Inhibition of both kinases may lead to disruption of the spindle assembly checkpoint (SAC) driving...
    Immunotherapy (Targeted), Small Molecule
    Not Required
    Solid Tumor
    MCD
    22-05
    MT-6402 may bind and kill both tumor and immune PD-L1 expressing cells in a manner consistent with SLTA mediated cellular cytotoxicity through ribosomal inactivation, independent...
    6402 is a 514 amino acid cytotoxic fusion protein, comprised of 3 distinct polypeptide domains described here from N to C-terminus, targeting PD-L1
    PD-L1
    Head and Neck Cancer, Non-Small Cell Lung Cancer, Solid Tumor
    MCD
    22-06
    ABSK061 inhibits FGFR2 and FGFR3. Inhibition of FGFR phosphorylation and signaling decreases cell viability. Selective inhibition avoids FGFR1 inhibition which potentially avoids side effects.
    targeted
    FGFR2/3
    Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, Other Solid Tumor, Solid Tumor
    MCD
    22-09
    CS5001 is a highly differentiated Antibody Drug Conjugate targeting ROR1. ROR1 is expressed across a variety of cancers, and may play an important role in...
    Antibody Drug Conjugate, Targeted Therapy
    Not Required
    Diffuse Large B-cell Lymphoma, Lymphoma, Solid Tumor, Triple Negative Breast Cancer
    MCD
    22-12
    UCT-01-097 may target, bind to and inhibit the activity of one or more kinases that play a key role in tumor cell proliferation.
    Small Molecule, Targeted Therapy
    Not Required
    Pancreatic Cancer, Solid Tumor
    MCD
    22-16
    BP1001 a liposome-incorporated Grb2 antisense oligodeoxynucleotide binds directly to and blocks Grb2 mRNA, thereby preventing Grb2 protein synthesis, leading to inhibition of cell proliferation of...
    Small Molecule
    Not Required
    Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer, Solid Tumor
    MCD
    22-17
    RMC-6236 inhibits the RAS(ON) state of multiple RAS variants both mutant and wild-type proteins.
    Small Molecule
    KRAS G12
    Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Solid Tumor
    MCD
    22-19
    NUV-868 is a small molecule bromodomain 2 (BD2)-selective bromodomain and extra-terminal domain (BET) inhibitor. The BET family of proteins have critical biological functions and are...
    Small Molecule
    Not Required
    Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Triple Negative Breast Cancer
    MCD
    22-20
    PEEL-223 is a small molecule topoisomerase 1 (TOP1) inhibitor, which may lead to inhibiting the repair of single-strand DNA breaks, DNA replication, and tumor cell...
    Small Molecule (Targeted)
    Not Required
    Solid Tumor
    MCD
    22-23
    ART0380 selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling,...
    Small Molecule, Targeted Therapy
    ATM Gene Alterations likely to predict loss of ATM protein
    Solid Tumor
    MCD
    22-31
    SIM1811-03, binds potently and selectively to TNFR2 and induces CD4 and CD8 T cell activation and proliferation. Targeting TNFR2 is anticipated to yield greater anti-tumor...
    Monoclonal Antibody
    Not Required
    Hepatocellular Cancer, Lymphoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Solid Tumor
    MCD
    22-35
    MRT-2359 induces degradation of GSPT1 and associated downregulation of MYC transcription factors and their transcriptional outputs, which may lead to preferential anti-proliferative activity in MYC-driven...
    Small Molecule
    Not Required
    Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Solid Tumor
    MCD
    22-39
    JAB-2485 is a small molecule Aurora A inhibitor. Inhibition of Aurora A activity at the cellular level, induces apoptosis and inhibits tumor growth.
    JAB-2485 is a small molecule Aurora A inhibitor
    Not Required
    Solid Tumor
    MCD
    23-01
    KSQ-4279 is a potent, selective small molecule inhibitor of USP1 that is being developed for the treatment of solid tumors.
    Cytotoxic, Small Molecule (Targeted)
    Monotherapy – Tumor Biopsy Cohort: have the following deleterious homologous recombination repair (HRR+) tumor mutations: BRCA1, BRCA2, PALB2, RAD51, RAD51B, RAD51C, RAD51D, BARD1, BRIP1, FANCA,...
    Solid Tumor
    23-02
    anti-GREM1 monoclonal antibody
    Monoclonal Antibody
    Not Required
    Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Non-Small Cell Lung Cancer, Other Solid Tumor, Prostate Cancer, Solid Tumor
    MCD
    23-03
    MDK-703 is an agonist of IL-7R
    Targeted Therapy
    Not Required
    Solid Tumor
    MCD
    23-04
    ASP1002 is anti-CLDN4 and anti-CD137 bispecific antibody
    Bispecific Antibodies
    Not Required
    Solid Tumor
    MCD
    23-05
    KT-253 is an MDM2 degrader
    targeted
    Not Required
    Lymphoma, Solid Tumor
    MCD
    23-06
    STX-478 is a PI3Kα small molecule inhibitor.
    Small Molecule
    PI3Kα
    Breast Cancer, Solid Tumor
    MCD
    23-09
    EO-3021 is an anti-CLDN18.2 antibody drug conjugate.
    Antibody Drug Conjugate
    CLDN18.2
    Esophageal Cancer, Gastric/GEJ Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumor
    MCD
    23-10
    ART6043 is a Polθ inhibitor
    Small Molecule
    *Genetic lesions known to cause loss of function of known DDR genes *Hormone-receptor status, breast cancer gene (BRCA) mutation
    Breast Cancer, Solid Tumor
    MCD
    23-15
    HF158K1 is a HER2-targeting antibody liposome
    Antibody Drug Conjugate (Monoclonal Antibody, Immunotherapy, targeted
    HER-2 positive or HER-2 low expression
    Solid Tumor
    MCD
    23-16
    INCB099280 is a PD-L1 inhibitor. Adagrasib is a KRAS inhibitor (G12C).
    Small Molecule Immunotherapy
    Not Required
    Colorectal Cancer, Non-Small Cell Lung Cancer, Solid Tumor
    MCD
    23-19
    RMC-9805 is a KRAS G12D inhibitor
    Small Molecule (Targeted)
    KRASG12D
    Solid Tumor
    MCD
    23-22
    GSK4524101 is a POLQ inhibitor
    Small Molecule
    Not Required
    Solid Tumor
    MCD
    23-23
    BH3120 is a PD-L1 x 4-1BB Bispecific Monoclonal Antibody
    Bispecific Antibodies
    PD-L1 positive expression
    Solid Tumor
    MCD
    23-24
    FB849 is a HPK1 inhibitor
    Immunotherapy (Targeted), Small Molecule
    Not Required
    Colorectal Cancer, Solid Tumor, Triple Negative Breast Cancer
    MCD
    23-28
    AT-1965 is a CMTR2 inhibitor
    Small Molecule (Targeted)
    Not Required
    Solid Tumor, Triple Negative Breast Cancer
    MCD
    JIT-20210023
    n/a
    n/a
    CDKN2A null, MTAP null
    Solid Tumor
    MCD
    JIT-ENV-ONC-101
    ENV- 101, a potent Hedgehog (Hh) pathway inhibitor
    n/a
    PTCH1 loss of function
    Solid Tumor
    MCD
    JIT-TSC-007
    n/a
    n/a
    Inactivating Alterations in TSC1 or TSC2
    Solid Tumor
    MCD

    Connect With Us

    Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.